Accuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification
The Radixact® System, based on the
"The use of SBRT is growing rapidly, offering patients an important option for treating tumors in fewer visits than with conventionally fractionated radiotherapy. This is a major benefit for the patient, but requires technology that can deliver the radiation dose with extreme accuracy and precision. ClearRT was designed to provide a major leap forward in delivering on this prerequisite," said
Excellent Images From the Start
ClearRT imaging provides:
- Versatility to fully image anatomy to be treated, regardless of size, with flexible fields of view
- Efficiency to increase patient throughput with reduced patient imaging and registration times
- Intelligence to evaluate plan adaptation and use images for re-planning, when appropriate, with high fidelity, highly Hounsfield unit (HU) accurate image quality
Learn more about ClearRT here.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the effect of ClearRT on the field of radiation oncology and clinical practice, clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts
+1 (408) 789-4426
bkaplan@accuray.com
Havas
+1 (703) 297-7194
christina.maginn@havas.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/accuray-expands-commercialization-of-clearrt-helical-fan-beam-kvct-imaging-for-the-radixact-system-with-ce-mark-certification-301309784.html
SOURCE